23,585 Shares in Novo Nordisk A/S $NVO Purchased by First Growth Capital LLC

First Growth Capital LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, Holdings Channel.com reports. The fund purchased 23,585 shares of the company’s stock, valued at approximately $1,150,000. Novo Nordisk A/S accounts for about 1.1% of First Growth Capital LLC’s portfolio, making the stock its 19th biggest holding.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NVO. Godfrey Financial Associates Inc. bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $25,000. WealthCollab LLC lifted its stake in shares of Novo Nordisk A/S by 93.5% during the 4th quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after acquiring an additional 260 shares during the last quarter. American National Bank & Trust bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth approximately $28,000. Maseco LLP purchased a new position in Novo Nordisk A/S during the 4th quarter valued at $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in Novo Nordisk A/S during the 4th quarter valued at $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy’s oral tablet is gaining traction in the U.K. and could provide Novo Nordisk with an early European launch path, which may help support future growth as it expands beyond injections. Article Title
• Positive Sentiment: Bank of America data indicates oral Wegovy is already accounting for roughly one-third of all Wegovy prescriptions, suggesting strong adoption and continued momentum in Novo Nordisk’s weight-loss franchise. Article Title
• Neutral Sentiment: Brokerages continue to rate Novo Nordisk as a “Hold,” reinforcing a wait-and-see view as the company balances growth opportunities against mounting operational and competitive pressures. Article Title
• Negative Sentiment: Novo Nordisk confirmed a security incident involving stolen clinical trial data after hackers reportedly demanded a $25 million ransom and began leaking information, raising concerns about data security, regulatory exposure, and reputational damage. Article Title

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Kepler Capital Markets lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Sanford C. Bernstein initiated coverage on shares of Novo Nordisk A/S in a research note on Wednesday, March 18th. They set an “outperform” rating and a $175.00 target price for the company. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 16th. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Finally, Nordea Equity Research lowered shares of Novo Nordisk A/S to a “hold” rating in a report on Tuesday, February 24th. Four equities research analysts have rated the stock with a Buy rating, eighteen have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and an average price target of $65.56.

Novo Nordisk A/S Price Performance

NVO opened at $43.20 on Friday. The company has a market capitalization of $192.89 billion, a price-to-earnings ratio of 10.14, a PEG ratio of 3.89 and a beta of 0.78. The company has a current ratio of 0.79, a quick ratio of 0.56 and a debt-to-equity ratio of 0.59. Novo Nordisk A/S has a 12-month low of $35.12 and a 12-month high of $74.38. The business’s fifty day simple moving average is $42.81 and its 200-day simple moving average is $45.86.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 earnings per share for the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%.The firm had revenue of $10.85 billion during the quarter. On average, equities research analysts anticipate that Novo Nordisk A/S will post 3.45 earnings per share for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.